Terms of Use
Updated: December 13, 2013
These Terms of Use are a binding agreement between you and STAAR, and governs your access and use of the Site, which includes any information, data, tools, products, services and other content (together, Content) available on or through the Site.
Please read these terms of use carefully before entering the site. Each time you enter the site, your use indicates your full acceptance of and agreement to abide by these terms of use in their then current form. If you do not accept the terms and conditions stated in these terms of use, please exit the site.
As we may revise the terms of use from time to time, you should review them periodically.
STAAR grants you a limited right to use the Site only for your own private, non-commercial informational purposes only, and to print pages from the Site only in connection with that use. You may not modify, distribute, transmit, perform, reproduce, publish, license, create derivative works from, transfer or sell any Content, including any text, graphics, logos and other source-identifying symbols, designs, icons, images, or other information, software or code obtained from the Site. You are prohibited from removing any copyright, trademark or other proprietary notice or legend contained on (or printed from) the Site or on any printed pages. In addition, you are prohibited from decomposing, decompiling, reverse engineering, disassembling or otherwise deconstructing all or any portion of the Site.
Important Safety Information
EVO & EVO TICL is designed for the correction of moderate to high near-sightedness (-0.5 to -20.0 dioptres (D)) and the reduction of near-sightedness in patients with up to -20 dioptres (D) of near-sightedness with less than or equal to 6.0 dioptres (D) of astigmatism. It is indicated for patients who are 21 to 45 years of age. In order to be sure that your surgeon will use a EVO with the most adequate power for your eye, your near-sightedness should be stable for at least a year before undergoing eye surgery. EVO surgery has been documented to safely and effectively correct near-sightedness between -0.5 dioptres (D) to -20.0 dioptres (D) and partially correct near-sightedness up to -20 dioptres in eyes with up to 6.0(D) of astigmatism. If you have near-sightedness within these ranges, EVO surgery may improve your distance vision without eyeglasses or contact lenses. EVO surgery does not eliminate the need for reading glasses, even if you have never worn them before. The EVO represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses. EVO is not intended to correct any astigmatism you may have. Implantation of the EVO is a surgical procedure, and as such, carries potentially serious risks. Please discuss the risks with your eye care provider. The following represent potential complications/adverse events reported in conjunction with refractive surgery in general: conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO surgery you should have a complete eye examination and talk with your eye care professional about EVO surgery, especially the potential benefits, risks and complications. You should discuss the time needed for healing after surgery.
Latin America
संदर्भ
1Visian ICL Patient Information Booklet
2Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.
3Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.